← SynDRA
TELMISARTAN
SynDRA canonical compound SYN0003165 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PPARG |
|---|
| Mechanism of action | Angiotensin receptor antagonist |
|---|
| Indication | hypertension |
|---|
| Disease area | cardiology |
|---|
All known targets
- AGTR1
- PPARG
- ABCG2
- ACE
- AGTR2
- Agtr1
- Agtr1b
- CYP2C19
- CYP2J2
- GLRA1
- PPARA
- SLC47A1
Mechanisms of action (all sources)
- Angiotensin receptor antagonist
- AGTR1 ANTAGONIST
- Type-1 angiotensin II receptor antagonist
Drug classes
- Angiotensin 2 Receptor Antagonists
- Angiotensin 2 Receptor Blocker
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Cardiovascular Agents
ATC classes
- C09C · ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
- ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Cross-references
Synonyms
- tolura
- micardis
- pritor
- Bibr-277se
- Kinzalmono
- Pritor
- Semintra
- Telmisartan actavis
- Telmisartan teva
- BIBR-277-SE
- BIBR-277
- C09CA07
- Kinzalmono (previously telmisartan boehringer ingelheim pharma kg)
- Micardis
- Telmisartan component of kinzalkomb
- Telmisartan component of micardis hct
- Telmisartan component of micardisplus
- Telmisartan component of onduarp
- Telmisartan component of pritorplus
- Telmisartan component of tolucombi
- Telmisartan component of twynsta
- Telmisartan teva pharma
- Tolura
- Kinzal
- Abbott brand of telmisartan
- Boehringer Ingelheim brand of telmisartan
- Glaxo Wellcome brand of telmisartan
- GlaxoSmithKline brand of telmisartan
- BIBR-277SE
- Bay 68-9291
- Micardis (TN)
- Telmisartan [USAN:INN]
- YM-086
- Telmisartan (JAN/USAN/INN)
- Micardis, Targit, Temax, BIBR277, Telmisartan
- 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
- 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
- 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
Reported adverse events
- Hypotension
- Back pain
- Upper respiratory tract infection
- Angioedema
- Abdominal pain
- Renal impairment
- Pharyngitis
- Cough
- Myalgia
- Dizziness
- Anaphylactic reaction
- Sinusitis
Look up TELMISARTAN in the interactive SynDRA portal →